After exiting stealth mode with $190M today, Marea Therapeutics' Co-Founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more

blonca9
Jun 18, 2024
1 min read

Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol, Marea's plans beyond this target, and his upcoming Timmerman Traverse hike for charity.

Recent Posts

See All

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

After exiting stealth mode with $190M today, Marea Therapeutics' Co-Founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight